Janssen's Preventive RSV Vaccine Receives FDA Breakthrough Therapy Designation, Addressing Critical Gap in Vaccination

Today, Janssen, a subsidiary of Johnson & Johnson, announced that the U.S. FDA has granted Breakthrough Therapy Designation to its investigational vaccine for the prevention of severe respiratory disease caused by respiratory syncytial virus (RSV) in adults aged 60 years and older. This Breakthrough Therapy Designation represents a significant breakthrough in the prevention of RSV infection.

RSV infection can affect individuals of all ages, but it is most dangerous in infants and the elderly. RSV can cause pneumonia, bronchitis, and other lower respiratory tract diseases. It is highly contagious, affecting more than 64 million people globally each year. Because the symptoms of RSV are difficult to distinguish from those of influenza or other respiratory infections, many patients infected with RSV may not receive an accurate diagnosis. In the United States, RSV leads to 177,000 hospitalizations among older adults annually, with 14,000 resulting in death. Due to the absence of preventive vaccines or effective antiviral therapies, RSV remains a significant health challenge and economic burden worldwide. It is estimated that in the United States, the annual hospitalization costs for patients aged 65 and older due to RSV exceed $1 billion.

Janssen’s RSV preventive vaccine is part of its vaccine portfolio under development, targeting areas with the highest unmet medical needs worldwide. This investigational RSV preventive vaccine leverages the unique features of Janssen’s adenoviral vector platform by packaging a transgene encoding the RSV fusion protein into an adenoviral vector.

This breakthrough therapy designation is based on clinical data from Janssen’s RSV vaccine. Compared with the current standard of care, the vaccine demonstrated clinically meaningful improvements. The RSV vaccine is currently in a Phase 2b proof-of-concept study, primarily evaluating its safety and efficacy in preventing RSV in adults aged 65 years and older.

“Since there are currently no preventive vaccines or effective antiviral therapies available, RSV remains a significant cause of illness in high-risk populations, particularly among elderly patients,” said Johan Van Hoof, Head of Infectious Diseases and Vaccine Research and Development at Janssen.MedicineThe doctor stated, “This Breakthrough Therapy designation represents a clear affirmation of the transformative potential of our RSV prevention solutions. We look forward to close collaboration with the FDA in the subsequent development of our RSV preventive vaccine.”

Source: WuXi AppTec